Rationale for targeting fibroblast growth factor receptor signaling in breast cancer - fgfr1 lobular breast cancer

Category

fgfr1 lobular breast cancer -


Feb 13, 2015 · The most common aberration is FGFR1 gene amplification (one of several putative oncogenes on 8p11-12), which is present in 7.5–17 % of all breast cancer and in 16–27 % of luminal B-type breast cancer (although variability in these numbers is expected, given the different methods used to assess amplification) [5–13].Cited by: 84. Infiltrating lobular breast cancer (ILC) is the most common special breast cancer subtype. With mutational or epigenetic inactivation of the cell adhesion molecule E-cadherin (CDH1) being confined almost exclusively to ILC, this tumor entity stands out from all other types of breast cancers.The molecular basis of ILC is linked to loss of E-cadherin, as evidenced by human CDH1 germline Cited by: 24.

Nov 15, 2006 · Purpose: Classic lobular carcinomas (CLC) account for 10% to 15% of all breast cancers. At the genetic level, CLCs show recurrent physical loss of chromosome16q coupled with the lack of E-cadherin (CDH1 gene) expression. However, little is known about the putative therapeutic targets for these tumors. The aim of this study was to characterize CLCs at the molecular genetic level and . Jun 27, 2019 · Invasive lobular carcinoma (ILC) is the most common special type of breast cancer, and is characterized by functional loss of E-cadherin, resulting in cellular adhesion defects.Author: Amy E. McCart Reed, Samir Lal, Samir Lal, Jamie R. Kutasovic, Leesa Wockner, Alan Robertson, Xavier.

Dec 27, 2012 · Lobular breast carcinoma usually shows poor responsiveness to chemotherapies and often lacks targeted therapies. Since FGFR1 expression has been shown to play pivotal roles in primary breast cancer tumorigenesis, we sought to analyze the status of FGFR1 gene in a metastatic setting of lobular breast carcinoma, since promising FGFR1 inhibitors has been recently developed.Cited by: 24. Jun 15, 2015 · In breast cancer, amplification of FGFR1- and/or 11q12-14 (which contains CCND1, FGF3, FGF4, and FGF19) have been observed in 23% of hormone receptor-positive (HR +), 27% of HER2-amplified, and 7% of triple-negative cases and is predictive for early relapses and poor outcome.Cited by: 169.

Dec 05, 2018 · The following article features coverage from the San Antonio Breast Cancer Symposium (SABCS) 2018 meeting. FGFR1/ZNF703 in 6%, and ZNF217 et al. Unraveling lobular breast cancer Author: Andrea S. Blevins Primeau, Phd, MBA. Mar 30, 2007 · Recent studies have demonstrated that specific FGFR1 amplification correlates with gene expression and that FGFR1 activity is required for the survival of a FGFR1 amplified breast cancer cell line. FGFR1 amplification was analysed in tissue microarrays comprising a cohort of 880 unselected breast tumours by means of chromogenic in situ Cited by: 289.

Feb 08, 2015 · Infiltrating lobular breast cancer (ILC) is the most common special breast cancer subtype. With mutational or epigenetic inactivation of the cell adhesion molecule E-cadherin (CDH1) being confined almost exclusively to ILC, this tumor entity stands out from all other types of breast cancers. The molecular basis of ILC is linked to loss of E-cadherin, as evidenced by human CDH1 germline Cited by: 24. Background: Lobular breast carcinoma usually shows poor responsiveness to chemotherapies and often lacks targeted therapies. Since FGFR1 expression has been shown to play pivotal roles in primary breast cancer tumorigenesis, we sought to analyze the status of FGFR1 gene in a metastatic setting of lobular breast carcinoma.